FOLFOXFOLFIRI5-FUoxaliplatinirinotecanCRCcolorectal cancer
… differential treatment responses (figure 3):First-line therapy FOLFOX: tumor progression in metastatic lesions.Second-line therapy FO…
7,227articles mentioning treatments
16,644treatment mentions
4,719distinct treatments extracted
0%of mentions human-reviewed
All extracted treatments
Showing 541–600 of 4,719, ordered by supporting articles. Choose a treatment to see its evidence.
Locoregional therapy3Pancreatic Enzyme Replacement Therapy3Peroral endoscopic myotomy3Pharmacologic treatment3Positive Airway Pressure (PAP) therapy3Regional analgesia3Traditional Chinese Medicine3Vitamin supplementation3advanced therapies3anti-PD1 therapy3anti-VEGF therapy3anti-programmed cell death protein-1 therapy3antiarrhythmic therapy3anticancer therapies3anticancer therapy3autologous stem cell transplantation3behavioural therapy3cancer therapies3chimeric antigen receptor T-cell therapy3clinical management3cognitive–behavioural therapy3conventional immunosuppression3coronary revascularisation3deworming3diabetes treatment3dopaminergic therapy3haematopoietic stem cell transplantation3immunotherapy treatment3inhaled corticosteroids3intensive care treatment3intravenous fluid therapy3intravenous iron therapy3lethal palliation3lifestyle changes3local anaesthesia3neurocritical care3novel therapies3nutritional support3occupational therapy3oral antibiotics3outpatient treatment3palliative chemotherapy3pharmacological interventions3physical rehabilitation3preventive measures3standard therapy3standard treatment3stent retriever thrombectomy3supportive treatment3surgical interventions3surgical management3symptomatic therapy3targeted treatment3topical therapy3tracheostomy3tyrosine kinase inhibitors3ultrasound-guided nerve blocks3vasodilator therapy3vasopressors3ventriculoperitoneal shunting3
Articles mentioning treatments
7,227 articles · page 229 of 603cancer vaccinesimmune checkpoint inhibitorsCOVID-19CellCartaOlink Reveal10x Genomics
…apies, such as immune checkpoint inhibitors, CAR-T cells, TILs, cancer vaccines, and T cell engagers/redirectors, work by inducing a robust T c…
cancer treatmentFDAInternational Council for HarmonisationFDA-recommended
…he development and quality control of cell therapy products for cancer treatment. As advanced therapies expand into clinical oncology, there is …
81.1%
radioimmunotherapieschimeric antigen receptor (CAR)-T cell therapiescancerOSU cohort3
…ntibodies (mAbs), antibody-drug conjugates (ADCs), bispecifics, radioimmunotherapies, and chimeric antigen receptor (CAR)-T cell therapies. 1 Howeve…
ASP-1929 PITHNSCCcuSCCPembrolizumabNational Institutes of HealthIRDye®700DXASP-1929NIH
…s Across Patients Show Consistent Immune Cell Changes Following ASP-1929 PIT. Uniform Manifold Approximation and Projection (UMAP) plot show…
CAR-T therapySolid tumorsPD-L1-EphA2-4-1BBPD-L1-EphA2-CD28EphA2-PD-L1-4-1BBPD-L1-EphA2EphA2-PD-L1-CD28
…findings support the clinical development of PD-L1-EphA2 tandem CAR-T therapy for treating solid tumors expressing either or both antigens, a…
249 CD3ε enhances CAR-T fitness and persistence by promoting the survival of effector memory T cells
CAR-T therapyCAR-T Cell TherapyB-cell malignanciesAAALAC-approved facilityCAR-T
…Background CAR-T therapy has demonstrated potent anti-tumor efficacy in treating a range…
CAR-T cell therapyCAR T cell therapyPancreatic Ductal Adenocarcinomapancreatic cancerMass General Brighamsolid tumorsMGH Cancer CenterAmerican-Italian Cancer FoundationCRIS Foundation Out-Back Fellowship Programmerotein+2 more
…Background CAR-T cell therapy has shown limited efficacy in solid tumors due to factors such …
CAR-T cell immunotherapiesCAR T cell immunotherapiessolid tumors
…Background CAR-T cell immunotherapies are being avidly pursued for treatment of solid tumors. However…
immune checkpoint blockadestandard treatmentsUniversity Hospital TübingenGerman Cancer Research CenterNUT carcinomaB7-H3NGS Core FacilityOmics IT and Data Management Core FacilityDKFZB7-H3-targeted
…nreported immunologically ‘hot’ NC tumors that may benefit from immune checkpoint blockade and other immunotherapies. To uncover novel actionable targets …
ACTsolid tumorshematologic cancersmetastatic melanomaRNF166
…highlighting a promising strategy for improving the efficacy of ACT.Abstract 277 Figure 1Comprehensive analysis of proteome turnove…
Trispecific NK cell engagersantibody-drug conjugatesUniversity of MinnesotacancerJackson Laboratoryhuman IL-15
…umors and evaluated against various IO therapies such as CAR T, Trispecific NK cell engagers, and antibody-drug conjugates.Results CD34 NSG-FLT3-IL15 mice e…